Skip to main content

FDA Approvals

FDA Oncology Update, FDA Approvals

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer

FDA Oncology Update, FDA Approvals

Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation

Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer

Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion

Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms

Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease

Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer

Page 7 of 53
Results 61 - 70 of 524